Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 5/20 | 0.54 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.54 |
| ▸ | KDR | P35968 | 5/20 | 0.46 |
| ▸ | MPO | P05164 | 3/20 | 0.46 |
| ▸ | PDE4A | P27815 | 1/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | SLC9A1 | P19634 | 3/20 | 0.40 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GPR3 | P46089 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16974026 | 0.82 | TLR7 (0.54) | TLR7TLR8KDRMPOPDE4A | |
| SCHEMBL254046 | 0.76 | TLR8 (0.50) | TLR7TLR8KDRMPOSLC9A1 | |
| SCHEMBL29311541 | 0.75 | TLR8 (0.49) | TLR7TLR8KDRMPOSLC9A1 | |
| SCHEMBL9229133 | 0.75 | TLR8 (0.49) | TLR7TLR8KDRMPOSLC9A1 | |
| SCHEMBL1234045 | 0.74 | TGFBR1 (0.49) | MPOLMNAKDM4EGPR3 | |
| SCHEMBL254210 | 0.74 | KDR (0.42) | TLR7TLR8KDRMPOSLC9A1 | |
| SCHEMBL3417268 | 0.73 | TLR8 (0.54) | TLR7TLR8KDRMPOSLC9A1 | |
| SCHEMBL10587719 | 0.71 | TLR7 (0.47) | TLR7MPOPDE4APDE4BPDE4C | |
| SCHEMBL9602914 | 0.71 | TLR7 (0.47) | TLR7MPOPDE4APDE4BPDE4C | |
| SCHEMBL15924453 | 0.71 | TLR7 (0.47) | TLR7MPOPDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216351-A1 | ADENOSINE A3 RECEPTOR ANTAGONISTS FOR TREATING AGING SKIN AND WOUNDS | ORADIN PHARMACEUTICAL LTD. (IL) | 2024-07-04 | — | — | US | disclosed |
| US-9668959-B2 | A3 adenosine receptor ligands for modulation of pigmentation | ORADIN PHARMACEUTICAL LTD. (IL) | 2017-06-06 | — | — | US | disclosed |
| EP-2456419-B1 | A3 ADENOSINE RECEPTOR LIGANDS FOR MODULATION OF PIGMENTATION | ORADIN PHARMACEUTICAL LTD (IL) | 2016-11-23 | — | — | EP | disclosed |
| US-20160136079-A1 | A3 ADENOSINE RECEPTOR LIGANDS FOR MODULATION OF PIGMENTATION | ORADIN PHARMACEUTICAL LTD. (IL) | 2016-05-19 | — | — | US | disclosed |
| US-9199102-B2 | A3 adenosine receptor ligands for modulation of pigmentation | ORADIN PHARMACEUTICAL LTD. (IL) | 2015-12-01 | — | — | US | disclosed |
| US-20120134945-A1 | A3 ADENOSINE RECEPTOR LIGANDS FOR MODULATION OF PIGMENTATION | ORADIN PHARMACEUTICAL LTD. (IL) | 2012-05-31 | — | — | US | disclosed |
| EP-2456419-A1 | A3 ADENOSINE RECEPTOR LIGANDS FOR MODULATION OF PIGMENTATION | Oradin Pharmaceutical Ltd. (IL) | 2012-05-30 | — | — | EP | disclosed |
| WO-2011010306-A1 | A3 ADENOSINE RECEPTOR LIGANDS FOR MODULATION OF PIGMENTATION | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2011-01-27 | — | — | WO | disclosed |
| EP-1827445-A2 | ENHANCING TREATMENT OF CANCER AND HIF-1 MEDIATED DISODERS WITH ADENOSINE A3 RECEPTOR ANTAGONISTS | King Pharmaceuticals Research and Development Inc. (US) | 2007-09-05 | — | — | EP | disclosed |
| WO-2007040565-A9 | ENHANCING TREATMENT OF CANCER AND HIF-1 MEDIATED DISODERS WITH ADENOSINE A3 RECEPTOR ANTAGONISTS | KING PHARMACEUTICALS RES & DEV (US) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007040565-A2 | ENHANCING TREATMENT OF CANCER AND HIF-1 MEDIATED DISODERS WITH ADENOSINE A3 RECEPTOR ANTAGONISTS | KING PHARMACEUTICALS RESEARCH & DEVELOPMENT, INC. (US) | 2007-04-12 | — | — | WO | disclosed |
| US-20060204502-A1 | Enhancing treatment of cancer and HIF-1 mediated disorders with adenosine A3 receptor antagonists | CREDIT SUISSE AG | 2006-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060204502-A1 | Enhancing treatment of cancer and HIF-1 mediated disorders with adenosine A3 receptor antagonists | HIF1A, HIF1AN, ADORA3 | TLR7 2580/4885TLR8 2361/4885KDR 326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.